Corwave is an early stage company focused on the development of innovative blood pumps. They are based on a disruptive technology, the wave membrane, which was developed by the CNRS and AMS R&D, and is protected by nine patent families. It mimics cardiac beating and preserves blood. Thanks to this technology, the Corwave VADs should limit the morbidities usually associated with those devices and improves the quality of life of those patients who suffer from chronic heart failure.

The company was founded in 2011 by European incubator MD Start.

Corwave is backed by major European Venture Capitalist funds and incorporated as a French SA. Our offices are located in central Paris at the Pepiniere Paris Sante Cochin.

CorWave is bringing a unique disruptive technology to these fast growing markets, estimated to have a potential worldwide value of several billion Euros.